Updated on 2025/10/01

写真a

 
NISHIBORI Nobuhiro
 
Organization
Nagoya University Hospital Nephrology Assistant Professor of Hospital
Title
Assistant Professor of Hospital

Degree 1

  1. 医学博士 ( 2025.3   名古屋大学 ) 

 

Papers 12

  1. Association of calciprotein particles with serum phosphorus among patients undergoing conventional and extended-hours haemodialysis Invited Reviewed

    Nobuhiro Nishibori

    Clinical kidney journal     2024.6

     More details

    Authorship:Lead author   Language:English  

  2. Longitudinal impact of extended-hours hemodialysis with a liberalized diet on nutritional status and survival outcomes: findings from the LIBERTY cohort Open Access

    Imaizumi, T; Okazaki, M; Hishida, M; Kurasawa, S; Nishibori, N; Nakamura, Y; Ishikawa, S; Suzuki, K; Takeda, Y; Otobe, Y; Kondo, T; Kaneda, F; Kaneda, H; Maruyama, S

    CLINICAL AND EXPERIMENTAL NEPHROLOGY   Vol. 29 ( 6 ) page: 818 - 830   2025.6

     More details

    Language:English   Publisher:Clinical and Experimental Nephrology  

    Background: Protein-energy wasting (PEW), a unique weight loss linked to nutritional and metabolic abnormalities, is common in patients undergoing hemodialysis (HD) and associated with adverse outcomes. This study investigated whether extended-hours HD combined with a liberalized diet could overcome PEW and improve survival. Methods: The body mass index (BMI) and survival outcomes in patients undergoing extended-hours HD were evaluated for up to 8 years using data from the LIBeralized diet Extended-houRs hemodialysis Therapy (LIBERTY) cohort. Extended-hours HD was defined as weekly dialysis length ≥ 18 h. Results: The LIBERTY cohort included 402 patients who initiated extended-hours HD. An increase in the length and frequency of HD sessions was observed over time, with approximately 70% and 20% of patients undergoing extended-hours HD for > 21 h/week and > 3 sessions/week at 5 years, respectively. The BMI and percentage creatinine generation rate were maintained over time, with no substantial increase in the phosphorus and potassium levels. The estimated BMI initially increased, and thereafter plateaued over time in patients with a baseline BMI < 25 kg/m<sup>2</sup>, whereas it decreased gradually in patients with a baseline BMI ≥ 25 kg/m<sup>2</sup> after several years from baseline. Ninety-one patients died, and 108 discontinued extended-hours HD during the median follow-up period of 6.2 years (interquartile range, 3.5–8.0), yielding a 5-year survival rate of 85%. Conclusions: Extended-hours HD with a liberalized diet may help achieve favorable survival outcomes and maintain nutritional status. Thus, it is a promising treatment option for managing PEW in patients undergoing HD.

    DOI: 10.1007/s10157-024-02602-7

    Open Access

    Web of Science

    Scopus

    PubMed

  3. Plasma Metabolite Profiles Between In-Center Daytime Extended-Hours and Conventional Hemodialysis Open Access

    Takami, N; Okazaki, M; Ozeki, T; Imaizumi, T; Nishibori, N; Kurasawa, S; Hishida, M; Akiyama, S; Saito, R; Hirayama, A; Kasuga, H; Kaneda, F; Maruyama, S

    KIDNEY360   Vol. 6 ( 3 ) page: 420 - 431   2025.3

     More details

    Language:English   Publisher:Kidney360  

    Key PointsSignificant differences in 39 plasma metabolites were observed between patients on extended-hours hemodialysis and those on conventional hemodialysis.Extended-hours hemodialysis had a lower lactate-to-pyruvate ratio and higher branched-chain amino acids than conventional hemodialysis.Extended-hours hemodialysis may have favorable metabolic and nutritional benefits for patients undergoing maintenance hemodialysis.BackgroundProtein-energy wasting, characterized by disordered body protein catabolism resulting from metabolic and nutritional derangements, is associated with adverse clinical outcomes in patients undergoing hemodialysis. Extended-hours hemodialysis (≥6 hours per treatment session) offers both enhanced removal of uremic solutes and better fluid management, generally allowing more liberalized dietary protein and calorie intake. The aim of this study was to evaluate the difference in plasma metabolite profiles among patients receiving in-center daytime extended-hours hemodialysis and those receiving conventional hemodialysis.MethodsPredialysis plasma samples were obtained from 188 patients on extended-hours hemodialysis (21.9 h/wk) and 286 patients on conventional hemodialysis (12.1 h/wk) in Japan in 2020 using capillary electrophoresis-mass spectrometry. Group differences were compared for 117 metabolites using Wilcoxon rank-sum tests with multiple comparisons and partial least squares discriminant analysis. In addition, propensity score-adjusted multiple regression analyses were performed to evaluate group differences for known uremic toxins, branched-chain amino acids, and lactate-to-pyruvate ratio (a possible surrogate marker of mitochondrial dysfunction).ResultsSignificant differences were observed in 39 metabolites, largely consistent with the high variable importance for prediction in partial least squares discriminant analysis. Among known uremic toxins, uridine and hypoxanthine levels were significantly higher in the conventional hemodialysis group than in the extended-hours hemodialysis group, whereas trimethylamine N-oxide levels were higher in the extended-hours hemodialysis group than in the conventional hemodialysis group. Patients on extended-hours hemodialysis had higher levels of all branched-chain amino acids and a lower lactate-to-pyruvate ratio than those on conventional hemodialysis (significant difference of -8.6 [95% confidence interval, -9.8 to -7.4]).ConclusionsExtended-hours hemodialysis was associated with a more favorable plasma metabolic and amino acid profile; however, concentrations of most uremic toxins did not significantly differ from those of conventional hemodialysis.

    DOI: 10.34067/KID.0000000675

    Open Access

    Web of Science

    Scopus

    PubMed

  4. Association of calciprotein particles with serum phosphorus among patients undergoing conventional and extended-hours haemodialysis Open Access

    Nishibori, N; Okazaki, M; Miura, Y; Hishida, M; Kurasawa, S; Imaizumi, T; Kato, N; Kosugi, T; Kuro-o, M; Kasuga, H; Kaneda, F; Maruyama, S

    CLINICAL KIDNEY JOURNAL   Vol. 17 ( 6 ) page: sfae121   2024.6

     More details

    Language:English   Publisher:Clinical Kidney Journal  

    Background and hypothesis: Extended-hours haemodialysis (HD) is associated with better clinical outcomes than conventional HD. We investigated whether extended-hours HD and conventional HD have varying effects on blood levels of calciprotein particles (CPPs) and phosphorus, which have been identified as major pathogenic molecules for vascular calcification. Methods: Patients who underwent conventional or extended in-centre daytime HD between January and March 2020 were included. Plasma CPP levels, representing only secondary CPPs (CPP-II), were measured in pre-dialysis samples. Linear and non-linear associations between CPPs and serum phosphorus levels were examined across dialysis modalities. Results: A total of 382 participants (185 undergoing extended-hours HD and 197 undergoing conventional HD) were included in the analysis. The median age of participants was 71 years, 65% of the patients were men and the mean phosphorus level was 5.4 mg/dl. Plasma CPP (CPP-II) levels were lower in the extended-hours HD group than in the conventional HD group [40 018 (arbitrary units) AU versus 75 728 AU; P <. 01]. Multivariable linear regression analysis showed that extended-hours HD was associated with lower natural logarithmic plasma CPP (CPP-II) levels: -0.64 (95% confidence interval -0.74 to -0.55). A restricted cubic spline function indicated that extended-hours HD was associated with lower plasma CPP (CPP-II) levels across levels of serum phosphorus, with significant differences observed between groups, especially in hyperphosphataemic conditions (P for interaction <.01). Conclusions: The extended-hours HD group had lower CPP levels than the conventional HD group despite no significant differences in serum phosphorus levels, which may contribute to better clinical outcomes in patients on extended-hours HD.

    DOI: 10.1093/ckj/sfae121

    Open Access

    Web of Science

    Scopus

    PubMed

  5. Relationship between peak aortic jet velocity and progression of aortic stenosis in patients undergoing hemodialysis

    Kurasawa, S; Imaizumi, T; Kondo, T; Hishida, M; Okazaki, M; Nishibori, N; Takeda, Y; Kasuga, H; Maruyama, S

    INTERNATIONAL JOURNAL OF CARDIOLOGY   Vol. 402   page: 131822   2024.5

     More details

    Language:English   Publisher:International Journal of Cardiology  

    Background: The natural history of aortic stenosis (AS) progression, especially before severe AS development, is not well documented. We aimed to investigate the time course of peak aortic jet velocity (Vmax) and AS progression risk according to baseline Vmax, particularly whether there is a Vmax threshold. Methods: In a retrospective multicenter cohort study of patients on hemodialysis with aortic valve calcification, we investigated the time series of Vmax and the relationship between the baseline Vmax and progression to severe AS by analyzing longitudinal echocardiographic data. Results: Among 758 included patients (mean age, 71 years; 65% male), patients with Vmax <1.5, 1.5–1.9, 2.0–2.4, 2.5–2.9, and 3.0–3.9 m/s were 395 (52%), 216 (29%), 85 (11%), 39 (5.1%), and 23 (3.0%), respectively. The Vmax slope was gradual (mean 0.05–0.07 m/s/year) at Vmax <2 m/s, but steeper (mean 0.13–0.21 m/s/year) at Vmax ≥2 m/s. During a median 3.2-year follow-up, 52 (6.9%) patients developed severe AS. While patients with Vmax <2 m/s rarely developed severe AS, the risk of those with Vmax ≥2 m/s increased remarkably with an increasing baseline Vmax; the adjusted incidence rates in patients with Vmax <1.5, 1.5–1.9, 2.0–2.4, 2.5–2.9, and 3.0–3.9 m/s were 0.59, 0.57, 4.25, 13.8, and 56.1 per 100 person-years, respectively; the adjusted hazard ratio per 0.2 m/s increase in the baseline Vmax was 1.49 (95% confidence interval: 1.32–1.68) when Vmax ≥2 m/s. Conclusions: The risk of progression to severe AS increased with the baseline Vmax primarily at ≥2 m/s; a Vmax threshold of 2 m/s was observed.

    DOI: 10.1016/j.ijcard.2024.131822

    Web of Science

    Scopus

    PubMed

  6. Calciprotein particles and phosphorus in conventional and extended-hours hemodialysis

    Nishibori, N; Okazaki, M; Imaizumi, T; Miura, Y; Kuro-O, M; Kasuga, H; Kaneda, F; Maruyama, S

    NEPHROLOGY DIALYSIS TRANSPLANTATION   Vol. 39   page: I2538 - I2538   2024.5

     More details

  7. Association between stopping renin-angiotensin system inhibitors immediately before hemodialysis initiation and subsequent cardiovascular events Open Access

    Nakamura, Y; Inaguma, D; Imaizumi, T; Kurasawa, S; Hishida, M; Okazaki, M; Fujishima, Y; Nishibori, N; Suzuki, K; Takeda, Y; Maruyama, S

    HYPERTENSION RESEARCH   Vol. 47 ( 5 ) page: 1372 - 1379   2024.3

     More details

    Language:English   Publisher:Hypertension Research  

    It is controversial whether renin-angiotensin system inhibitors (RASIs) should be stopped in patients with advanced chronic kidney disease (CKD). Recently, it was reported that stopping RASIs in advanced CKD was associated with increased mortality and cardiovascular (CV) events; however, it remains unclear whether stopping RASIs before dialysis initiation affects clinical outcomes after dialysis, which this study aimed to evaluate. In this multicenter prospective cohort study in Japan, we included 717 patients (mean age, 67 years; 68% male) who had a nephrology care duration ≥90 days, initiated hemodialysis, and used RASIs 3 months before hemodialysis initiation. The multivariable adjusted Cox models were used to compare mortality and CV event risk between 650 (91%) patients who continued RASIs until hemodialysis initiation and 67 (9.3%) patients who stopped RASIs. During a median follow-up period of 3.5 years, 170 (24%) patients died and 228 (32%) experienced CV events. Compared with continuing RASIs, stopping RASIs was unassociated with mortality (adjusted hazard ratio [aHR]: 0.82; 95% confidence interval [CI]: 0.50–1.34) but was associated with higher CV events (aHR: 1.59; 95% CI: 1.06–2.38). Subgroup analyses showed that the risk of stopping RASIs for CV events was particularly high in patients aged <75 years, with a significant interaction between stopping RASIs and age. This study revealed that patients who stopped RASIs immediately before dialysis initiation were associated with subsequent higher CV events. Active screening for CV disease may be especially beneficial for these patients. (Figure presented.)

    DOI: 10.1038/s41440-024-01616-8

    Open Access

    Web of Science

    Scopus

    PubMed

  8. 特集 血液浄化法に応じた食と栄養 4.長時間血液透析(2)今日から実践可能な,透析患者の低栄養への根本的対策

    菱田 学, 岡崎 雅樹, 西堀 暢浩, 今泉 貴広, 金田 史香, 丸山 彰一

    臨床透析   Vol. 39 ( 12 ) page: 1397 - 1404   2023.11

     More details

    Publisher:日本メディカルセンター  

    DOI: 10.19020/cd.0000002767

    CiNii Research

  9. Rationale and study design of a randomized controlled trial to investigate the renoprotective effect of canagliflozin assessed by test of renal hemodynamics in diabetic kidney disease (the FAGOTTO study) Open Access

    Kato, S; Kuwatsuka, Y; Ando, M; Tatematsu, Y; Nishibori, N; Maruyama, S

    BMC NEPHROLOGY   Vol. 24 ( 1 ) page: 228   2023.8

     More details

    Language:English   Publisher:BMC Nephrology  

    Background: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are considered to have the potential to maintain renal function by correcting glomerular hypertension in patients with diabetic kidney disease (DKD). The aim of this study is to demonstrate the renoprotective effect of SGLT2i by measuring renal hemodynamics, including glomerular filtration fraction (FF), in type 2 diabetic patients with moderate renal dysfunction. Methods: Renoprotective effect of canagliflozin derived from test of renal hemodynamics in diabetic kidney disease (FAGOTTO) study is a 12-week multicenter, open-label, randomized (1:1), parallel-group trial of type 2 diabetic patients with diabetic kidney disease (30 ≤ estimated glomerular filtration rate [eGFR] ≤ 60 mL/min/1.73 m<sup>2</sup>). A total of 110 patients are to be randomly allocated to receive once-daily canagliflozin 100 mg or control (standard therapy). FF will be calculated by dividing the measured GFR (mGFR) by the effective renal plasma flow (eRPF). mGFR and eRPF will be measured by the clearance of inulin and para-aminohippuric acid (PAH), respectively. The primary endpoint of this trial is the percentage change in FF after 4 weeks of treatment in the canagliflozin and control groups. Discussion: The FAGOTTO study will elucidate the mechanism of the renoprotective action of SGLT2i. The background, rationale, and study design of this trial are presented. To date, > 80 patients have been enrolled in this trial. The study will end in 2025. Trial registration: jRCT (Japan Registry Of Clinical Trials) jRCTs041200069. Date of registration: November 27, 2020.

    DOI: 10.1186/s12882-023-03277-0

    Open Access

    Web of Science

    Scopus

    PubMed

  10. Number of calcified aortic valve leaflets: natural history and prognostic value in patients undergoing haemodialysis Open Access

    Kurasawa, S; Okazaki, M; Imaizumi, T; Kondo, T; Hishida, M; Nishibori, N; Takeda, Y; Kasuga, H; Maruyama, S

    EUROPEAN HEART JOURNAL-CARDIOVASCULAR IMAGING   Vol. 24 ( 7 ) page: 909 - 920   2023.6

     More details

    Language:English   Publisher:European Heart Journal Cardiovascular Imaging  

    Aims: Aortic valve calcification in aortic sclerosis, a precursor of aortic stenosis (AS), is not always present in all three leaflets; how calcification develops in each leaflet is unknown. We aimed to investigate the natural history of calcification development in each aortic valve leaflet and the prognostic value of the number of calcified leaflets. Methods and results: In a retrospective multicentre cohort study of patients undergoing haemodialysis without AS, we observed calcification development in each aortic valve leaflet using echocardiography. We investigated the association between the number of calcified leaflets and AS development and mortality using time-to-event analysis. Among the 1507 patients (mean age, 66 years; 66% male) included in the longitudinal echocardiography analysis, 709 (47%) had aortic sclerosis at baseline: one-leaflet calcified, 370 (52%); two-leaflet calcified, 215 (30%); and three-leaflet calcified, 124 (17%). The median time for one calcified leaflet increase was 3-4 years, and 251 (17%) patients developed AS during a median 3.2-year follow-up. The increased number of calcified aortic valve leaflets was associated with developing AS; compared with that of one-leaflet calcified, the adjusted hazard ratios (aHRs) [95% confidence intervals (CIs)] of two- and three-leaflet calcified were 2.12 (1.49-3.00) and 4.43 (3.01-6.52), respectively; the aHR (95% CI) per one calcified leaflet increase was 2.24 (1.96-2.55). It was also associated with all-cause mortality; the aHR (95% CI) per one calcified leaflet increase was 1.18 (1.08-1.27). Conclusion: The number of calcified aortic valve leaflets strongly predicted AS development and even mortality in patients undergoing haemodialysis, suggesting the usefulness of assessing calcification for each valve leaflet separately using echocardiography.

    DOI: 10.1093/ehjci/jead020

    Open Access

    Web of Science

    Scopus

    PubMed

  11. A digest of the Evidence-Based Clinical Practice Guideline for Nephrotic Syndrome 2020 Reviewed

    Takehiko Wada

    Clin Exp Nephrol   Vol. 25 ( 12 ) page: 1277 - 1285   2021.12

     More details

    Language:English  

    DOI: 10.1007/s10157-021-02098-5.

  12. Dipeptidyl peptidase-4 inhibitors-associated bullous pemphigoid: A retrospective study of 168 pemphigoid and 9,304 diabetes mellitus patients Reviewed Open Access

    Yohei Kawaguchi

    J Diabetes Investig   Vol. 10 ( 2 ) page: 392 - 398   2019.5

     More details

    Language:English  

    DOI: 10.1111/jdi.12877.

    Open Access

▼display all

Books 3

  1. CKDガイドライン

    ( Role: Contributor ,  CKD患者のシックデイにおける薬剤の中止)

  2. Medical Practice

    ( Role: Contributor)

    2025.5 

     More details

    Total pages:164   Responsible for pages:4   Language:Japanese Book type:Textbook, survey, introduction

  3. IgA腎症の疫学(レジストリーからいえること)

    小山 恵理子( Role: Joint author ,  解析、データ作成)

    日本臨牀  2024.12 

     More details

    Total pages:7   Responsible for pages:7   Language:Japanese

Presentations 12

  1. 長時間透析がHepcidin25に与える影響

    西堀 暢浩

    第70回日本透析医学会学術集会・総会  2025.6.28  日本透析学会

     More details

    Event date: 2025.6

    Language:Japanese   Presentation type:Oral presentation (general)  

    Venue:大阪   Country:Japan  

  2. 長時間透析が維持透析患者における高IL-6環境に対する生体反応性に与える影響

    西堀 暢浩

    第68回日本腎臓学会学術総会  2025.6.21  日本腎臓学会

     More details

    Event date: 2025.6

    Language:Japanese   Presentation type:Poster presentation  

    Venue:横浜   Country:Japan  

  3. Association of erythropoietin resistance index with interleukin-6 among patients undergoing conventional and extended-hours haemodialysis International conference

    Nobuhiro Nishibori

    2024.10.24  American Society of Nephrology

     More details

    Event date: 2024.10

    Language:English   Presentation type:Poster presentation  

    Venue:San Diego Convention Center   Country:United States  

  4. カナグリフロジンが、中等度腎機能低下を伴う2型糖尿病患者の腎血行動態に与える影響FAGOTTO study

    西浩暢浩

    第67回日本腎臓学会学術総会  2024.6.30 

     More details

    Event date: 2024.6

    Language:Japanese   Presentation type:Oral presentation (general)  

  5. Calciprotein particles and phosphorus in conventional and extended-hours hemodialysis International conference

    ERA24 Congress  2024.5.24  Christoph Wanner

     More details

    Event date: 2024.5

    Language:English   Presentation type:Poster presentation  

    Venue:Stockholmsmässan Mässvägen 1 Älvsjö 125 80 Stockholm   Country:Sweden  

  6. The FAGOTTO study: Randomized controlled trial for impact on renal hemodynamics of the SGLT2 inhibitor canagliflozin in diabetic kidney disease International conference

    ASN kidney week 2023  2023.11.3 

     More details

    Event date: 2023.11

    Language:English   Presentation type:Poster presentation  

    Country:United States  

  7. 長時間透析患者におけるフラッシュグルコースモニタリングを用いた血糖のトレンド把握

    西堀暢浩

    日本腎臓学会学術総会  2022.6.11 

     More details

    Event date: 2022.6

    Language:Japanese  

  8. 長時間透析による目標ヘモグロビン値の検討

    山田 拓弥

    第70回日本透析医学会学術集会・総会  2025.6.28  日本透析学会

     More details

    Event date: 2025.6

    Language:Japanese   Presentation type:Oral presentation (general)  

    Venue:大阪   Country:Japan  

  9. カヘキシアにおける血中メタボライトの網羅的検討

    岡崎 雅樹

    第70回日本透析医学会学術集会・総会  2025.6.28  日本透析学会

     More details

    Event date: 2025.6

    Language:Japanese   Presentation type:Oral presentation (general)  

    Venue:大阪   Country:Japan  

  10. 長時間透析における透析後疲労と関連因子

    石川 重史

    第70回日本透析医学会学術集会・総会  2025.6.29  日本透析学会

     More details

    Event date: 2025.6

    Language:Japanese   Presentation type:Oral presentation (general)  

    Venue:大阪   Country:Japan  

  11. 長時間透析における透析前後リン値と生命予後

    石川 重史

    第68回日本腎臓学会学術総会  2025.6.22  日本腎臓学会

     More details

    Event date: 2025.6

    Language:Japanese   Presentation type:Poster presentation  

    Venue:横浜   Country:Japan  

  12. 長時間透析によるエリスロポエチン抵抗性改善の機序解明

    山田 拓弥

    第68回日本腎臓学会学術総会  2025.6.21  日本腎臓学会

     More details

    Event date: 2025.6

    Language:Japanese  

    Venue:横浜   Country:Japan  

▼display all

Other research activities 1

  1. JRBR

    2022.4

     More details

    JRBRにおける日本の腎生検統計の報告を4カ月おきに行っている

KAKENHI (Grants-in-Aid for Scientific Research) 1

  1. 尿アルカリ化効果を伴う抗尿酸薬による補体活性化と進行性慢性腎臓病抑制への病態解明

    Grant number:25K11519  2025.4 - 2028.3

    科学研究費助成事業  基盤研究(C)

    加藤 佐和子, 水野 正司, 西堀 暢浩, 尾関 貴哉

      More details

    Authorship:Coinvestigator(s) 

    慢性腎臓病(CKD)の進行抑制には、尿細管間質障害の制御が必須である。尿中補体活性化終末産物である膜侵襲複合体(MAC)は腎機能障害の進行をもたらす。CKD患者の代謝性アシドーシスによる尿pHの低下は、補体活性化を増幅し、尿細管間質でのMACの形成から炎症・障害を惹起し、腎間質の線維化を進め不可逆な腎障害に至る。慢性腎臓病が原因の酸排泄障害による代謝性アシドーシスの治療はアルカリ化剤による補正であり、今回の検証で予後や合併症の抑制機序を示す明確なエビデンスを構築する。代謝性アシドーシスを伴ったCKD患者のアルカリ化剤による積極治療が、補体の活性化を制御し、腎保護効果をもたらすことを実証する。